Lani
06-22-2012, 11:40 AM
fail to be "cured" with adjuvant herceptin ie, will progress to Stage IV (early bc is Stages I, II and III)
?
If true, this could help those patients start on another anti-her2 drug or combinations of drugs so they don't end up as Stage IVs ( as well as save governments/insurance companies a lot of money)
[Anticancer Research]
Elevated HER2 Extracellular Domain Level in Primary Breast Cancer with HER2 Overexpression Predicts Early Failure of Adjuvant Trastuzumab
SEBASTIEN THUREAU1⇓,
FLORIAN CLATOT2,
SOPHIE LABERGE-LE-COUTEULX3,
MARC BARON4,
JEAN-PIERRE BASUYAU5 and
EMMANUEL BLOT6
+ Author Affiliations
1Department of Radiotherapy, Henri Becquerel Center, Rouen, France
2Department of Medical Oncology, Henri Becquerel Center, Rouen, France
3Department of Pathology, Henri Becquerel Center, Rouen, France
4Department of Surgery, Henri Becquerel Center, Rouen, France
5Department of Clinical Biology Laboratory, Henri Becquerel Center, Rouen, France
6Department of Medical Oncology, Oncology Center, Vannes, France
Correspondence to: Sébastien Thureau, Department of Radiotherapy, Henri Becquerel Center, Rue d'Amiens, 76000 Rouen, France. Tel: + 33 664323023, Fax: +33 232082504, e-mail: sebastien.thureau@chb.unicancer.fr
Abstract
Aim: To investigate in a prospective study the prognostic value of serum HER2 extracellular domain (ECD) level in patients with primary breast cancer overexpressing HER2 treated with adjuvant chemotherapy and trastuzumab. Patients and Methods: All the patients treated for primary breast cancer with chemotherapy and adjuvant trastuzumab from April 1, 2005 to December 31, 2006 at the Centre de Lutte Contre le Cancer de Haute Normandie were enrolled in this prospective study. HER2 ECD was measured in frozen serum by a commercial kit with a cut-off value of 15 ng/ml. Results: Sixty-five patients were enrolled. Seven patients (11%) had an elevated serum HER2 ECD level (mean=25.1 ng/ml, range 15.1-38.9 ng/ml). During follow-up, 13 patients (20%) developed metastases and seven patients (11%) died. Death was related to breast cancer metastases in six patients (9%). Out of the seven patient with elevated serum HER2 ECD level, five (71%) developed metastases and three (43%) died of metastases during follow-up. Multivariate analysis showed that elevated serum HER2 ECD level was the unique factor for both disease-free survival (p<0.0006) and overall survival (p=0.008) in this series. Conclusion: Elevated serum HER2 ECD level is a strong prognostic factor in primary breast cancer overexpressing HER2 treated with adjuvant therapy of trastuzumab. In addition, our results suggest that it could predict failure of adjuvant therapy of trastuzumab.
Received February 10, 2012.
Revision received March 15, 2012.
Accepted March 16, 2012.
Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
?
If true, this could help those patients start on another anti-her2 drug or combinations of drugs so they don't end up as Stage IVs ( as well as save governments/insurance companies a lot of money)
[Anticancer Research]
Elevated HER2 Extracellular Domain Level in Primary Breast Cancer with HER2 Overexpression Predicts Early Failure of Adjuvant Trastuzumab
SEBASTIEN THUREAU1⇓,
FLORIAN CLATOT2,
SOPHIE LABERGE-LE-COUTEULX3,
MARC BARON4,
JEAN-PIERRE BASUYAU5 and
EMMANUEL BLOT6
+ Author Affiliations
1Department of Radiotherapy, Henri Becquerel Center, Rouen, France
2Department of Medical Oncology, Henri Becquerel Center, Rouen, France
3Department of Pathology, Henri Becquerel Center, Rouen, France
4Department of Surgery, Henri Becquerel Center, Rouen, France
5Department of Clinical Biology Laboratory, Henri Becquerel Center, Rouen, France
6Department of Medical Oncology, Oncology Center, Vannes, France
Correspondence to: Sébastien Thureau, Department of Radiotherapy, Henri Becquerel Center, Rue d'Amiens, 76000 Rouen, France. Tel: + 33 664323023, Fax: +33 232082504, e-mail: sebastien.thureau@chb.unicancer.fr
Abstract
Aim: To investigate in a prospective study the prognostic value of serum HER2 extracellular domain (ECD) level in patients with primary breast cancer overexpressing HER2 treated with adjuvant chemotherapy and trastuzumab. Patients and Methods: All the patients treated for primary breast cancer with chemotherapy and adjuvant trastuzumab from April 1, 2005 to December 31, 2006 at the Centre de Lutte Contre le Cancer de Haute Normandie were enrolled in this prospective study. HER2 ECD was measured in frozen serum by a commercial kit with a cut-off value of 15 ng/ml. Results: Sixty-five patients were enrolled. Seven patients (11%) had an elevated serum HER2 ECD level (mean=25.1 ng/ml, range 15.1-38.9 ng/ml). During follow-up, 13 patients (20%) developed metastases and seven patients (11%) died. Death was related to breast cancer metastases in six patients (9%). Out of the seven patient with elevated serum HER2 ECD level, five (71%) developed metastases and three (43%) died of metastases during follow-up. Multivariate analysis showed that elevated serum HER2 ECD level was the unique factor for both disease-free survival (p<0.0006) and overall survival (p=0.008) in this series. Conclusion: Elevated serum HER2 ECD level is a strong prognostic factor in primary breast cancer overexpressing HER2 treated with adjuvant therapy of trastuzumab. In addition, our results suggest that it could predict failure of adjuvant therapy of trastuzumab.
Received February 10, 2012.
Revision received March 15, 2012.
Accepted March 16, 2012.
Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved